Under terms of the merger agreement, Roche will commence a tender offer to acquire all of Poseida's outstanding shares for a price of $9.00 per share in cash at closing, plus a non-tradeable CVR to ...
Taldefgrobep was well-tolerated in the RESILIENT trial with 97% of subjects continuing into the optional long-term extension, which will remain open and ongoing pending discussion with FDA. There were ...